Recent investigations have focused on the overlap of glucagon-like peptide-1|GIP|GCGR activator therapies and dopamine signaling. While GCGR activators are commonly employed for addressing type 2 diabetes, their unexpected consequences on motivation circuits, specifically influenced by dopaminerg